PRED MILD (prednisolone acetate) by AbbVie is clinical pharmacology prednisolone acetate is a glucocorticoid that, on the basis of weight, has 3 to 5 times the anti-inflammatory potency of hydrocortisone. First approved in 1972.
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
PRED MILD is a prednisolone acetate ophthalmic suspension approved in 1972 for ocular inflammatory conditions. It is a potent glucocorticoid with 3-5x the anti-inflammatory potency of hydrocortisone, reducing edema, fibrin deposition, and phagocytic migration in acute ocular inflammation. It is administered as topical eye drops to suppress inflammatory responses in conditions such as post-operative ocular inflammation and allergic conjunctivitis.
With LOE approaching and modest Part D utilization (~3,300 claims annually), this mature product faces generic erosion and operates with a lean commercial team focused on retention.
CLINICAL PHARMACOLOGY Prednisolone acetate is a glucocorticoid that, on the basis of weight, has 3 to 5 times the anti-inflammatory potency of hydrocortisone. Glucocorticoids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery
Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.
A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte
Comparison of Hylastan to Methylprednisolone Acetate in Patients With Symptomatic Osteoarthritis of the Knee
A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery
Worked on PRED MILD at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPRED MILD offers minimal career growth potential given zero linked job openings and approaching LOE status. Roles on this product are typically defensive, focused on protecting market share against generics and managing a legacy brand with modest commercial footprint (~$800K annual Part D spend).